Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Brian Yang

Beijing-based Brian Yang is a senior writer in charge of overall China coverage within the APAC Pharma news team. A veteran journalist, he has written extensively on pharmaceutical R&D, regulatory affairs and market access for PharmAsia News. Brian’s intimate industry knowledge and in-depth analysis has won wide praise and helped secure exclusive interviews with top biopharma executives.
He has led a team of writers to provide industry-leading coverage on key issues such as multi-regional clinical trials, priority reviews and go-to-market strategies in a highly-dynamic and fast-changing market, with the on-the-ground coverage consistently ranked among the top-read in PharmAsia News.

Prior to joining Informa, Brian worked as a foreign affairs correspondent for two TV networks and web editor for an international radio station. Trilingual in Mandarin Chinese, English and Japanese, he obtained his BA degree from China and an MA degree from Japan.

Latest From Brian Yang

'We Must Innovate': US Biotechs Chart New Growth Path In China

Facing a increasingly competitive environment and tense bilateral relationship, US biotechs must innovate and differentiate while protecting their innovations in China, say panelists at the BIO annual conference.

China Business Strategies

US 500m Dose Donation Takes Shine From China Vaccine Diplomacy

The Biden Administration’s pledge to provide 500 million doses of Pfizer/BioNTech's COVID-19 vaccines is a direct blow to China’s global vaccine diplomacy push.

China Coronavirus COVID-19

China Reg Express: Anti-Blocking Law, Inspection Guideline And Gene Therapy Follow-Up Studies

A sweeping "anti-blocking" law, patent legislation, gene therapy study guidance and new regulations on inspections are all within a flurry of regulatory activity in China.

China Legislation

US 500m Dose Donation Takes Shine From China Vaccine Diplomacy

The Biden Administration’s pledge to provide 500 million doses of Pfizer/BioNTech's COVID-19 vaccines is a direct blow to China’s global vaccine diplomacy push.

China Coronavirus COVID-19

Pharma Missing Out From Market Access Challenges In China: EU Group

Slower approvals for foreign drugs, a volume-based procurement scheme and localization requirements caused nearly 80% of respondent European pharma firms to miss out on opportunities in China, where they also continue to decouple from headquarters in a “in China-for-China” strategy, a survey from a prominent EU business group shows.

China Market Access

Asia Deal Watch: Heartseed Licenses Lead Cell Therapy Candidate To Novo Nordisk

Novo gets worldwide development and commercial rights except for Heartseed’s home market in Japan. LianBio unveils licensing partnerships with Lyra, Landos and Nanobiotix.

Deals Business Strategies
See All
UsernamePublicRestriction

Register